6/5/2019

Tobramycin Sulfate Injection

Products Affected - Description

- Tobramycin Sulfate solution for injection, Akorn, 40 mg/mL, 2 mL vial, 25 count, NDC 17478-0114-02 - discontinued
- Tobramycin Sulfate solution for injection, Akorn, 40 mg/mL, 30 mL vial, 1 count, NDC 17478-0114-30 - discontinued
- Tobramycin Sulfate solution for injection, Teva, 40 mg/mL, 2 mL vial, 25 count, NDC 00703-9402-04 - discontinued
- Tobramycin Sulfate solution for injection, Teva, 40 mg/mL, 30 mL vial, 1 count, NDC 00703-9416-01 - discontinued

Reason for the Shortage

- Akorn discontinued tobramycin injection in late-2018.
- Mylan Institutional refuses to provide availability information.
- Pfizer had tobramycin injection on shortage due to manufacturing delays.
- Teva discontinued tobramycin injection.

Available Products

- Tobramycin Sulfate solution for injection, Baxter, 40 mg/mL, 2 mL vial, 25 count, NDC 36000-0244-25
- Tobramycin Sulfate solution for injection, Baxter, 40 mg/mL, 30 mL vial, 1 count, NDC 36000-0242-01
- Tobramycin Sulfate lyophilized powder for solution for injection, Fresenius Kabi, 1.2 gram, 50 mL preservative-free vial, 6 count, NDC 63323-0303-51
- Tobramycin Sulfate solution for injection, Fresenius Kabi, 10 mg/mL, 2 mL vial, 25 count, NDC 63323-0305-02
- Tobramycin Sulfate solution for injection, Fresenius Kabi, 40 mg/mL, 2 mL vial, 25 count, NDC 63323-0306-02
- Tobramycin Sulfate solution for injection, Fresenius Kabi, 40 mg/mL, 30 mL vial, 10 count, NDC 63323-0306-30
- Tobramycin Sulfate solution for injection, Fresenius Kabi, 40 mg/mL, 50 mL vial, 1 count, NDC 63323-0307-51
- Tobramycin Sulfate solution for injection, Pfizer, 40 mg/mL, 2 mL vial, 25 count, NDC 00409-3578-01
- Tobramycin Sulfate lyophilized powder for solution for injection, X-Gen, 1.2 gram, 50 mL preservative-free vial, 1 count, NDC 39822-0412-01
- Tobramycin Sulfate lyophilized powder for solution for injection, X-Gen, 1.2 gram, 50 mL preservative-free vial, 6 count, NDC 39822-0412-06

Estimated Resupply Dates

- All marketed presentations that we are able to get information on are available.

Updated

Updated June 5, 2019 by Michelle Wheeler, PharmD, Drug Information Specialist. Created May 28, 2010 by Jane Chandramouli, PharmD, Drug Information Specialist. © 2019, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins

Subscribe to AHFS Clinical Drug Information to get direct access to integrated drug shortages content, plus comprehensive and actionable drug information.